Higher Scientific Officer in Molecular Addictions

Institute of Cancer Research - Cancer Therapeutics

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Under the leadership of our Chief Executive, Professor Paul Workman FMedSci, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally. The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

The Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The division’s exciting goal is to discover high quality drug candidates for validated biological targets and to progress these candidates to clinical trial. All the scientific disciplines are in place to make this possible. Our chemists work alongside world-class biologists and drug metabolism specialists focusing on new molecular targets emerging from human genome and ground breaking cell biology research.

A Higher Scientific Officer (HSO) position is available immediately in our Molecular Addictions Team to characterise the molecular mechanisms of resistance to AKT inhibitors with distinct mechanisms of action. The project aims to identify novel aspects of AKT signalling that may be regulated through non-catalytic functions. The HSO will also provide technical and intellectual support to other members of the Molecular Addictions team who will be working on various related projects. Our strategy involves a combination of molecular pharmacology, transcriptional profiling, and mass spectrometry approaches. This platform will also allow us to identify novel therapeutic targets in AKT-addicted tumours.

Applicants should possess a Master’s or PhD degree in molecular biology/cell biology/molecular pharmacology or a related subject. Previous experience of basic cell and molecular biology or biochemistry in a work-based laboratory environment is required. Solid experience in cell culture is also required. Duties will also include general maintenance of the lab (e.g. preparation of common reagents, ordering, and maintenance of plasmid and cell line databases).

Salary will start at £31,669 and will be for 3 years in the first instance. This post also benefits from generous annual leave entitlement and defined benefit pension scheme. Further information can be found below in the full job description

Positive Action Statement: We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.

Share this job
     
  Share by Email   Print this job   More sharing options
We value your feedback on the quality of our adverts. If you have a comment to make about the overall quality of this advert, or its categorisation then please send us your feedback
Advert information

Type / Role:

Location(s):

London